ECSP056009A - Regimenes contraceptivos transdermicos extendidos - Google Patents

Regimenes contraceptivos transdermicos extendidos

Info

Publication number
ECSP056009A
ECSP056009A EC2005006009A ECSP056009A ECSP056009A EC SP056009 A ECSP056009 A EC SP056009A EC 2005006009 A EC2005006009 A EC 2005006009A EC SP056009 A ECSP056009 A EC SP056009A EC SP056009 A ECSP056009 A EC SP056009A
Authority
EC
Ecuador
Prior art keywords
progestogen
cycle
therapy
contraception
days
Prior art date
Application number
EC2005006009A
Other languages
English (en)
Inventor
Andrew Joseph Friedman
Guardia Katherine D La
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP056009A publication Critical patent/ECSP056009A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Se describe un método de contracepción que comprende el paso de administrar a una mujer que menstrúa un ciclo de terapia contraceptiva, dicho ciclo de terapia incluyendo, por cuando menos 42 días sucesivos, la administración de una combinación de un estrógeno y un progestágeno en una dosificación diaria contraceptivamente efectiva, en donde dicho progestágeno es un progestágeno inhibidor de sulfatasa potente, y dicho ciclo de terapia incluye 4 a 8 días que están libres de la administración de estrógeno, después de dichos por lo menos 42 días sucesivos; se describe también un método de contracepción, que provee control mejorado del sangrado y continuación e índices de satisfacción mejorados en mujeres que menstrúan usando el método.
EC2005006009A 2003-03-11 2005-09-08 Regimenes contraceptivos transdermicos extendidos ECSP056009A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/385,597 US20030219471A1 (en) 2002-03-11 2003-03-11 Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens

Publications (1)

Publication Number Publication Date
ECSP056009A true ECSP056009A (es) 2006-07-28

Family

ID=32987305

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005006009A ECSP056009A (es) 2003-03-11 2005-09-08 Regimenes contraceptivos transdermicos extendidos

Country Status (12)

Country Link
US (1) US20030219471A1 (es)
EP (1) EP1613293A1 (es)
KR (1) KR20070006543A (es)
CN (1) CN1771024A (es)
AU (1) AU2003252139A1 (es)
BR (1) BR0318192A (es)
CA (1) CA2517778A1 (es)
CR (1) CR8010A (es)
EC (1) ECSP056009A (es)
MX (1) MXPA05009656A (es)
RU (1) RU2005128284A (es)
WO (1) WO2004080442A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
SI1453521T1 (sl) 2001-12-05 2013-11-29 Teva Women's Health, Inc. Oralni kontraceptiki za preprečevanje nosečnosti in zmanjševanje predmenstrualne simptomatike
EP1624848A4 (en) 2003-05-02 2009-02-25 Duramed Pharmaceuticals Inc METHOD FOR HORMONY TREATMENT WITH CONTRAZEPTVA SCHEMATES WITH EXTENDED CYCLE
US7816546B2 (en) * 2003-06-30 2010-10-19 Richter Gedeon Vegyeszeti Gyar Rt. Process for the synthesis of high purity d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-oxime
CA2771944A1 (en) 2003-07-16 2005-01-27 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
US20070111975A1 (en) * 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
MX2007004120A (es) * 2004-10-07 2007-06-15 Duramed Pharmaceuticals Inc Metodos de tratamiento hormonal utilizando regimentes de ciclo prolongado de dosis ascendente.
WO2007106264A2 (en) * 2006-03-02 2007-09-20 Warner Chilcott Company, Inc. Extended cycle multiphasic oral contraceptive method

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3545397A (en) * 1969-03-17 1970-12-08 Dowty Technical Dev Ltd Air-cushion vehicles and like craft
IL48277A (en) * 1974-10-18 1978-03-10 Schering Ag Vaginal ring
US4292965A (en) * 1978-12-29 1981-10-06 The Population Council, Inc. Intravaginal ring
US5188835A (en) * 1986-06-16 1993-02-23 Kabi Pharmacia Ab Intravaginal devices
SE8602666D0 (sv) * 1986-06-16 1986-06-16 Leo Ab Intravaginal devices
US4906463A (en) * 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
US5006342A (en) * 1986-12-22 1991-04-09 Cygnus Corporation Resilient transdermal drug delivery device
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5252334A (en) * 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
DE4344463A1 (de) * 1993-12-22 1995-06-29 Schering Ag Kombinationsprodukt zur Kontrazeption
IL122432A (en) * 1995-06-07 2000-07-16 Cygnus Therapeutic Systems Transdermal patch for preventing ovulation
CA2478336A1 (en) * 2002-03-11 2003-09-25 Janssen Pharmaceutica N.V. Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens

Also Published As

Publication number Publication date
CN1771024A (zh) 2006-05-10
WO2004080442A1 (en) 2004-09-23
CA2517778A1 (en) 2004-09-23
CR8010A (es) 2009-01-16
MXPA05009656A (es) 2006-03-08
BR0318192A (pt) 2006-03-21
US20030219471A1 (en) 2003-11-27
EP1613293A1 (en) 2006-01-11
KR20070006543A (ko) 2007-01-11
RU2005128284A (ru) 2006-02-10
AU2003252139A1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
ECSP056009A (es) Regimenes contraceptivos transdermicos extendidos
AR048722A1 (es) Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos
DK365887D0 (da) Kombinationsdoseringsform til hormonbehandling af kvinder i prae-menopausen
PL323729A1 (en) Skin sticking plaster and method of administering sole 17-deacetyl norgestimate or together with estrogen
NZ516502A (en) Administration of non-oral androgenic steroids to women having an elevated level of sex hormone binding globulin (SHBG)
EA200201000A1 (ru) Гормон-заместительная терапия
AR028809A1 (es) Un metodo anticonceptivo y una unidad anticonceptiva oral trifasica
ES2174265T3 (es) Regimenes de progestogeno-anti-progestogeno.
BG104451A (en) Antiestrogen and progestin-containing peroral contraceptives
PT1150683E (pt) Utilizacao de dienogest em doses elevadas
DK1937274T3 (da) Anvendelse af estradiolvalerat i kombination med dienogest til oral behandling af dysfunktionel uterin blødning i enhed med en oral kontraception
Stika Emergency postcoital contraception
Singh et al. Endometriosis-what is New in Medical Management with Progesterones